ストックスクリーナーアプリを入手
38.60
0.44%
0.17
アフターアワーズ：
38.60
前日終値:
$38.43
開ける：
$38.34
24時間の取引高:
5.27M
Relative Volume:
1.28
時価総額：
$16.49B
収益：
$2.31B
当期純損益:
$1.66B
株価収益率:
16.80
EPS:
2.297
ネットキャッシュフロー:
$827.02M
1週間 パフォーマンス:
+0.55%
1か月 パフォーマンス:
-0.13%
6か月 パフォーマンス:
+10.57%
1年 パフォーマンス:
+58.98%
1日の値動き範囲:
$38.20
$38.81
1週間の範囲:
$37.83
$38.90
52週間の値動き範囲:
$24.32
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
RPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.60 | 16.42B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma (NASDAQ:RPRX) EVP Sells $3,060,375.22 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 30,654 Shares of Stock - MarketBeat
Royalty Pharma : Q4 2025 Pre-Quarterly Results Communication - marketscreener.com
How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Royalty Pharma PLC $RPRX Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Dividend Watch: How Royalty Pharma plc stock compares to growth peers - Улправда
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 69,582 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares - MarketBeat
Royalty Pharma Insider Sold Shares Worth $766,420, According to a Recent SEC Filing - marketscreener.com
VP Urist Sells 20,000 ($766.4K) Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Nigeria
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln - MSN
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Shareholder Sandy Lamm LLC Files To Sell 160,000 Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - TipRanks
Royalty Pharma stock rises after acquiring cancer drug royalties By Investing.com - Investing.com Nigeria
Royalty Pharma stock rises after acquiring cancer drug royalties - Investing.com India
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - The Manila Times
Royalty Pharma acquires royalty interest in cancer drugs for $315 million - Investing.com
Royalty Pharma acquires royalty interest in cancer drugs for $315 million By Investing.com - Investing.com UK
Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma acquires drug royalty rights for up to $315 million - StreetInsider
Royalty Pharma (Nasdaq: RPRX) buys Nuvalent NSCLC royalties for up to $315M - Stock Titan
Royalty Pharma (RPRX): Revisiting Valuation After Fresh Analyst Upgrades and Strengthening Buy-Side Consensus - Sahm
Squarepoint Ops LLC Makes New $9.85 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Buys 41,830 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Adage Capital Partners GP L.L.C. Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX - MarketBeat
TD Cowen Maintains Royalty Pharma (RPRX) Buy Recommendation - Nasdaq
TD Cowen raises Royalty Pharma stock price target on growth outlook By Investing.com - Investing.com South Africa
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - news.stocktradersdaily.com
TD Cowen Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
RPRX: TD Cowen Raises Price Target for Royalty Pharma | RPRX Sto - GuruFocus
TD Cowen raises Royalty Pharma stock price target on growth outlook - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' - StreetInsider
First Trust Advisors LP Has $39.78 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Sells 268,263 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $913,526.10 in Stock - MarketBeat
Royalty Pharma EVP Sells Over $1.6 Million in Shares - TradingView — Track All Markets
Hsbc Holdings PLC Sells 77,498 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Raised by Amundi - MarketBeat
Denali enters into a $275M funding deal with Royalty Pharma - MSN
What Royalty Pharma (RPRX)'s Denali Rare-Disease Royalty Deal and Cash Surge Means For Shareholders - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Sells $4,374,700.00 in Stock - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing - marketscreener.com
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Royalty Pharma (RPRX): Assessing Valuation After a Strong Multi‑Month Share Price Rally - Sahm
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
2.79%
大文字化:
|
ボリューム (24 時間):